Modulation of cabozantinib efficacy by the prostate tumor microenvironment
Metrics: PDF 512 views | HTML 1069 views | ?
Manisha Tripathi1,*, Srinivas Nandana1,*, Sandrine Billet1, Karen A. Cavassani1, Rajeev Mishra1, Leland W.K. Chung1, Edwin M. Posadas1 and Neil A. Bhowmick1,2
1Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California 90048, USA
2Department of Research, Greater Los Angeles Veterans Administration, Los Angeles, California 90048, USA
*These authors have contributed equally to this work
Neil A. Bhowmick, email: firstname.lastname@example.org
Edwin M. Posadas, email: Edwin.Posadas@cshs.org
Keywords: carcinoma associated fibroblasts, cabozantinib, metastasis, prostate cancer
Received: May 30, 2017 Accepted: August 15, 2017 Published: September 23, 2017
The tumor microenvironment (TME) is increasingly recognized as the arbiter of metastatic progression and drug resistance in advanced prostate cancer (PCa). Cabozantinib is a potent tyrosine kinase inhibitor (TKI) with reported biological activity in the PCa epithelia, but failed to provide an overall survival benefit in phase 3 clinical trials. However, the promising biologic efficacy of the drug in early trials warranted a better understanding of the mechanism of action, with the goal of improving patient selection for TKI-based therapy such as cabozantinib. We found a 100-fold lower cabozantinib IC50 in macrophages, PCa associated fibroblasts, and bone marrow fibroblasts compared to PCa epithelia. In PCa mouse models, pre-treatment with cabozantinib potentiated osseous and visceral tumor engraftment, suggesting a pro-tumorigenic host response to the drug. We further found that the host effects of cabozantinib impacted bone turnover, but not necessarily tumor expansion. Cabozantinib affected M1 macrophage polarization in mice. Analogously, circulating monocytes from PCa patients treated with cabozantinib, demonstrated a striking correlation of monocyte reprograming with therapeutic bone responsivity, to support patient selection at early stages of treatment. Thus, a re-evaluation of TKI-based therapeutic strategies in PCa can be considered for suitable patient populations based on TME responses.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.